Please login to the form below

Not currently logged in
Email:
Password:

Grifols to buy Talecris for $3.4bn

Grifols SA, Europe's largest maker of blood-plasma products has agreed to buy US biotherapeutics company Talecris for approximately $3.4bn

Grifols SA, Europe's largest maker of blood-plasma products has agreed to buy US biotherapeutics company Talecris for approximately $3.4bn in cash and stock to expand its share to almost a third of the US market.

Under the deal, Grifols will pay $19 in cash and 0.641 shares of Grifols for each of Talecris' shares. The price represents a 533 per cent premium to the average closing price of Talecris common stock over the last 30 days. The total offer, including net debt, is approximately $4bn.

The acquisition will add to Grifols' earnings in the first year, with a 'meaningful' boost beginning in the second year, a company statement announced yesterday.

The deal gives Grifols the same share of the $7bn US market for blood-based infusions as Baxter International and more than CSL's 29 per cent share, according to analysts.

In 2008, Australia's CSL entered into an agreement to buy Talecris in an all-cash deal valued at $3.1bn. However the companies cancelled the merger after the US Federal Trade Commission (FTC) failed to approve the deal based on anti-trust grounds.

Victor Grifols, CEO of Grifols, said he didn't foresee any problems with regulators this time round: "This operation is very different from the previous one," he said.

"Grifols is a much smaller competitor than CSL in the US and we don't see any conflict that may leave the FTC uncomfortable about the combination of the two companies."

Talecris recorded a 12 per cent rise in sales last year, reaching $1.53bn, while the company's profit more than doubled to $153.9m. Grifols said the combined company will have annual revenue of about $2.8bn.

The transaction is expected to close in the second half of 2010.

8th June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....

Infographics